| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.lupin.com | |
| Market Cap | 74,991.40 Cr. | |
| Enterprise Value(EV) | 76,892.29 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 39.30 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 41.87 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 41.93 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 304.06 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 5.41 | Calculated using Price: 1,645.45 |
| Dividend Yield | 0.24 | Period Ending 2023-03 |
| No. of Shares Subscribed | 45.58 Cr. | 455,750,104 Shares |
| FaceValue | 2 | |
| About Lupin Ltd. | ||
| Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. Lupin is recognised as one of the world's largest manufacturers of Tuberculosis drugs. The company have significant market share across multiple therapy areas such as Cardiovascular (prils and statins), Diabetology, Asthma, Paediatric, Central Nervous System (CNS), Gastro Intestinal (GI), Anti-Infective (AI) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). To add to this, the company has proud to maintain over the years its global leadership positions in other therapy areas such as Anti-TB and Cephalosporin. | ||
| 1 Day |
|
+0.45% |
| 1 Week |
|
+2.38% |
| 1 Month |
|
+1.68% |
| 3 Month |
|
+10.85% |
| 6 Month |
|
+45.38% |
| 1 Year |
|
+132.13% |
| 2 Year |
|
+120.79% |
| 5 Year |
|
+89.45% |
| 10 Year |
|
+65.99% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 31.09 | 22.85 | 21.05 | 1.94 | 3.88 | -3.09 | 9.47 | -11.79 | 3.68 | |
| Return on Capital Employed (%) | 40.3 | 24.42 | 18.57 | 3.56 | 7.97 | 5.45 | 9.71 | -7.11 | 6.06 | |
| Return on Assets (%) | 21.08 | 12.84 | 10.6 | 1 | 1.97 | -1.54 | 5.09 | -6.7 | 2.01 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 8,874 | 11,163 | 13,498 | 13,577 | 13,742 | 12,537 | 13,803 | 12,153 | 12,465 | 13,239 | |
| Non Curr. Liab. | 426 | 6,032 | 6,447 | 6,876 | 7,296 | 3,003 | 1,136 | 1,153 | 992 | 984 | |
| Curr. Liab. | 3,729 | 5,061 | 6,121 | 5,096 | 6,130 | 9,225 | 8,436 | 8,276 | 9,265 | 8,921 | |
| Minority Int. | 24 | 32 | 35 | 40 | 47 | 44 | 55 | 69 | 78 | 68 | |
| Equity & Liab. | 13,054 | 22,289 | 26,100 | 25,589 | 27,215 | 24,810 | 23,430 | 21,651 | 22,800 | 23,213 | |
| Non Curr. Assets | 5,221 | 12,402 | 14,147 | 13,379 | 13,362 | 9,396 | 9,444 | 9,194 | 10,349 | 10,624 | |
| Curr. Assets | 7,832 | 9,887 | 11,953 | 12,201 | 13,854 | 15,413 | 13,986 | 12,458 | 12,451 | 12,588 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 13,054 | 22,289 | 26,100 | 25,589 | 27,215 | 24,810 | 23,430 | 21,651 | 22,800 | 23,213 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 12,770 | 14,139 | 17,494 | 15,804 | 14,665 | 15,375 | 15,163 | 16,405 | 16,642 | 19,480 | |
| Other Income | 240 | 185 | 107 | 150 | 333 | 484 | 136 | 214 | 151 | 146 | |
| Total Income | 13,010 | 14,324 | 17,601 | 15,955 | 14,998 | 15,859 | 15,299 | 16,619 | 16,793 | 19,626 | |
| Total Expenditure | -9,150 | -10,454 | -13,001 | -12,657 | -12,104 | -13,020 | -12,596 | -16,190 | -14,921 | -16,106 | |
| PBIDT | 3,859 | 3,871 | 4,600 | 3,298 | 2,894 | 2,839 | 2,703 | 429 | 1,871 | 3,520 | |
| Interest | -10 | -59 | -153 | -204 | -302 | -363 | -141 | -143 | -274 | -333 | |
| Depreciation | -435 | -487 | -912 | -1,086 | -846 | -970 | -887 | -1,659 | -881 | -1,004 | |
| Taxation | -970 | -1,059 | -979 | -288 | -888 | -1,157 | -449 | -137 | -269 | -373 | |
| Exceptional Items | -1,464 | -340 | -752 | ||||||||
| PAT | 2,444 | 2,270 | 2,565 | 258 | 521 | -400 | 1,228 | -1,509 | 448 | 1,810 | |
| Minority Interest | -41 | -9 | -7 | -7 | -9 | 0 | -11 | -19 | -18 | -19 | |
| Share Associate | |||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | 2,403 | 2,261 | 2,557 | 251 | 607 | -269 | 1,217 | -1,528 | 430 | 1,791 | |
| Adjusted EPS | 53 | 50 | 57 | 6 | 13 | -6 | 27 | -34 | 9 | 39 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 2,004 | 2,733 | -382 | 4,114 | 1,751 | 1,666 | 1,469 | 1,822 | 367 | 1,897 | |
| Cash Fr. Inv. | -859 | -1,055 | -6,962 | -2,527 | 470 | -3,282 | 1,107 | -1,240 | 1,292 | -1,287 | |
| Cash Fr. Finan. | -857 | -197 | 5,836 | 433 | -1,492 | 744 | -891 | -1,885 | -1,572 | -337 | |
| Net Change | 288 | 1,482 | -1,508 | 2,019 | 729 | -872 | 1,685 | -1,303 | 87 | 273 | |
| Cash & Cash Eqvt | 607 | 2,108 | 780 | 2,799 | 1,416 | 544 | 2,229 | 926 | 1,013 | 1,265 |
|
Wed, 01 May 2024
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. Intimation Under Regulation 30 of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. |
|
Tue, 30 Apr 2024
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. |
|
Tue, 30 Apr 2024
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. Intimation under Regulation 30 of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. |
| Tue, 30 Apr 2024 |
Higher Delivery Quantity
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Making Higher Highs for 3 days
|
Close Within 52 Week High Zone
|
